FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone415-978-1200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$212.96 million
Profitability
Miscellaneous
Employees461
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
FibroGen (NASDAQ:FGEN) Frequently Asked Questions
What is FibroGen's stock symbol?
FibroGen trades on the NASDAQ under the ticker symbol "FGEN."
How were FibroGen's earnings last quarter?
FibroGen Inc (NASDAQ:FGEN) issued its earnings results on Thursday, August, 8th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.49) by $1.75. The biopharmaceutical company earned $191.57 million during the quarter, compared to analysts' expectations of $29.03 million. FibroGen had a return on equity of 9.01% and a net margin of 13.90%. The business's revenue for the quarter was up 335.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.28) EPS. View FibroGen's Earnings History.
When is FibroGen's next earnings date?
What price target have analysts set for FGEN?
6 brokers have issued twelve-month price objectives for FibroGen's shares. Their forecasts range from $40.00 to $71.00. On average, they anticipate FibroGen's share price to reach $58.40 in the next twelve months. This suggests a possible upside of 50.5% from the stock's current price. View Analyst Price Targets for FibroGen.
What is the consensus analysts' recommendation for FibroGen?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for FibroGen.
Has FibroGen been receiving favorable news coverage?
News stories about FGEN stock have trended somewhat negative recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. FibroGen earned a daily sentiment score of -1.5 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for FibroGen.
Are investors shorting FibroGen?
FibroGen saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 4,520,000 shares, a decrease of 5.8% from the August 30th total of 4,800,000 shares. Based on an average daily volume of 562,300 shares, the short-interest ratio is presently 8.0 days. Approximately 5.9% of the company's stock are short sold. View FibroGen's Current Options Chain.
Who are some of FibroGen's key competitors?
Some companies that are related to FibroGen include Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Perrigo (PRGO), Catalent (CTLT) and Jazz Pharmaceuticals (JAZZ).
What other stocks do shareholders of FibroGen own?
Who are FibroGen's key executives?
FibroGen's management team includes the folowing people:
- Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 65)
- Mr. Pat Cotroneo, Sr. VP of Fin. & CFO (Age 55)
- Dr. K. Peony Yu, Chief Medical Officer (Age 57)
- Mr. Julian N. Stern, Sec. (Age 94)
- Dr. Barry A. Berkowitz, Founder
When did FibroGen IPO?
(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.
Who are FibroGen's major shareholders?
FibroGen's stock is owned by many different of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.34%), Envestnet Asset Management Inc. (0.03%), Woodstock Corp (0.01%), NJ State Employees Deferred Compensation Plan (0.01%), Bailard Inc. (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, Gerald Lema, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.
Which major investors are selling FibroGen stock?
FGEN stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Woodstock Corp and Bailard Inc.. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, Elias Kouchakji, James A Schoeneck, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz and Thomas B Neff. View Insider Buying and Selling for FibroGen.
Which major investors are buying FibroGen stock?
FGEN stock was purchased by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, NJ State Employees Deferred Compensation Plan, Envestnet Asset Management Inc. and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for FibroGen.
How do I buy shares of FibroGen?
Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is FibroGen's stock price today?
One share of FGEN stock can currently be purchased for approximately $38.80.
How big of a company is FibroGen?
FibroGen has a market capitalization of $3.37 billion and generates $212.96 million in revenue each year. The biopharmaceutical company earns $-86,420,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. FibroGen employs 461 workers across the globe.View Additional Information About FibroGen.
What is FibroGen's official website?
How can I contact FibroGen?
FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]
MarketBeat Community Rating for FibroGen (NASDAQ FGEN)
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe FGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
